Log in

NASDAQ:MRKRTapImmune Stock Price, Forecast & News

$1.89
-0.04 (-2.07 %)
(As of 08/13/2020 04:00 PM ET)
Add
Compare
Today's Range
$1.86
Now: $1.89
$2.07
50-Day Range
$1.75
MA: $2.00
$2.20
52-Week Range
$1.33
Now: $1.89
$6.54
Volume424,000 shs
Average Volume394,860 shs
Market Capitalization$88.11 million
P/E RatioN/A
Dividend YieldN/A
Beta1.04
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes novel cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company is developing TPIV100/110, which is in Phase II clinical trial to treat human epidermal growth factor receptor 2 breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. It is also developing a proprietary nucleic acid-based antigen expression technology, PolyStart, to improve the ability of the immune system to recognize and destroy diseased cells. The company is headquartered in Houston, Texas.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.15 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MRKR
CUSIPN/A
CIKN/A
Phone713-400-6400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$210,000.00
Book Value$0.96 per share

Profitability

Net Income$-21,430,000.00

Miscellaneous

Employees11
Market Cap$88.11 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$1.89
-0.04 (-2.07 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MRKR News and Ratings via Email

Sign-up to receive the latest news and ratings for MRKR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











TapImmune (NASDAQ:MRKR) Frequently Asked Questions

How has TapImmune's stock price been impacted by Coronavirus?

TapImmune's stock was trading at $1.98 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, MRKR stock has decreased by 4.5% and is now trading at $1.89.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of TapImmune?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TapImmune in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for TapImmune
.

When is TapImmune's next earnings date?

TapImmune is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for TapImmune
.

How were TapImmune's earnings last quarter?

TapImmune Inc. (NASDAQ:MRKR) announced its earnings results on Monday, August, 10th. The company reported ($0.14) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.14).
View TapImmune's earnings history
.

What price target have analysts set for MRKR?

6 brokers have issued twelve-month target prices for TapImmune's shares. Their forecasts range from $2.50 to $16.00. On average, they expect TapImmune's share price to reach $8.42 in the next year. This suggests a possible upside of 345.3% from the stock's current price.
View analysts' price targets for TapImmune
.

Has TapImmune been receiving favorable news coverage?

News coverage about MRKR stock has been trending positive on Friday, InfoTrie reports. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. TapImmune earned a coverage optimism score of 2.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about TapImmune
.

Who are some of TapImmune's key competitors?

What other stocks do shareholders of TapImmune own?

Who are TapImmune's key executives?

TapImmune's management team includes the following people:
  • Mr. Peter L. Hoang MBA, Pres, CEO & Director (Age 47)
  • Mr. Anthony H. Kim, Chief Financial Officer (Age 43)
  • Mr. Michael J. Loiacono, Chief Accounting Officer, Treasurer & Sec. (Age 53)
  • Dr. Ann M. Leen, Chief Scientific Officer
  • Ms. Elizabeth Donnelly, Director of Admin.

What is TapImmune's stock symbol?

TapImmune trades on the NASDAQ under the ticker symbol "MRKR."

How do I buy shares of TapImmune?

Shares of MRKR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TapImmune's stock price today?

One share of MRKR stock can currently be purchased for approximately $1.89.

How big of a company is TapImmune?

TapImmune has a market capitalization of $88.11 million and generates $210,000.00 in revenue each year. The company earns $-21,430,000.00 in net income (profit) each year or ($0.47) on an earnings per share basis. TapImmune employs 11 workers across the globe.

What is TapImmune's official website?

The official website for TapImmune is www.markertherapeutics.com.

How can I contact TapImmune?

TapImmune's mailing address is 3200 Southwest Freeway Suite 2240, Houston TX, 77027. The company can be reached via phone at 713-400-6400 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.